➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Baxter
Medtronic
McKesson
AstraZeneca

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,217,057

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,217,057 protect, and when does it expire?

Patent 8,217,057 protects XALKORI and is included in one NDA.

This patent has twenty-five patent family members in twenty-one countries.

Summary for Patent: 8,217,057
Title:Polymorphs of a c-MET/HGFR inhibitor
Abstract: This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Tran-Dube; Michelle Bich (San Diego, CA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/095,116
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 8,217,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,217,057

PCT Information
PCT FiledNovember 23, 2006PCT Application Number:PCT/IB2006/003383
PCT Publication Date:June 14, 2007PCT Publication Number: WO2007/066185

International Family Members for US Patent 8,217,057

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 057964   Start Trial
Australia 2006323025   Start Trial
Brazil PI0619420   Start Trial
Canada 2632283   Start Trial
China 101326175   Start Trial
Cyprus 1113843   Start Trial
Denmark 1963302   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Express Scripts
Johnson and Johnson
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.